Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson

by Kathy Jones on  August 7, 2012 at 7:35 PM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

Tests for a new therapy to treat Alzheimer's disease have been halted by Pfizer and Johnson & Johnson as the new drug failed to meet expectations.
 Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson
Tests for New Alzheimer Drug Halted by Pfizer and Johnson & Johnson

The final, phase 3 trial of the intravenous bapineuzumab therapy did not meet targets for effectiveness in aiding cognitive and functional performance of Alzheimer's victims, according to the two drug giants.

As a result, they decided to end the program to develop the treatment, they said.

"We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease and their caregivers," said Steven Romano, senior vice president at Pfizer Inc.

"Yet these data, and the subgroup and biomarker analyses under way, will further inform our understanding of this complex disease and advance research in this field."

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Alzheimers Disease Drug Toxicity Signature Drug Toxicity Top Ten Selling Drugs Creutzfeldt-Jakob Disease Diet and Alzheimer´s Disease Genetics of Alzheimer´s disease Modified Atkins Diet: All You Need to Know 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive